On August 16, 2021,Sino Biological Inc. (stock abbreviation: Sino Biological) successfully listed on the Growth Enterprise Market of Shenzhen Stock Exchange (stock code: 301047). Sino Biological publicly issued 17 million shares and raised 4.98 billion yuan. The issue price is RMB 292.92 per share. It is worth mentioning that the issue price surpasses Roborock Technology and becomes the most expensive new share in the history of A-shares. The opening rose 104.8% to 599.90 yuan per share.
Public information shows that Sino Biological was established in 2016 and is a biotechnology company mainly engaged in the research and development, production, sales and technical services of biological reagents. Its main business includes recombinant proteins, antibodies, genes and culture media and other products, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services, it also provides preclinical scale production services for monoclonal antibody drug candidates for pharmaceutical companies or biotechnology companies.
In the first quarter of 2021, Sino Biological's revenue was 457 million yuan, a year-on-year increase of 311.16%; net profit was 332 million yuan, a year-on-year increase of 417.92%.
From 2018 to 2020, Sino Biological achieved operating revenues of approximately 139 million yuan, 181 million yuan, and 1.596 billion yuan respectively, and the corresponding realized net profits were 36 million yuan, 36 million yuan, and 1.128 billion yuan respectively.
It is worth noting that in the early stage of the outbreak of the coronavirus in 2020, Sino Biological quickly developed a series of virus-related proteins, antibodies and other biological reagent products based on the biological reagent R&D and production technology platform and research and development experience, it timely met the needs of global industrial and scientific research customers for related reagents in basic research, drug and vaccine development, and virus detection, and promoted rapid growth in business performance.
